SiRNA targeting VEGF can inhibit HCC growth and tumor angiogenesis in vivo [28], and has anti-tumor efficacy for patients with HCC under hypoxic conditions [29]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.